NAVIGATION 

Bioidentical Hormone Replacement Therapy (BHRT)

Although BHRT is an age old remedy, many doctors and their patients are just learning of this option. BHRT is in the forfront of anti-aging treatment and for many doctors the newest method for helping cure much that ails the menopausal woman as well as the andropausal male. Bioidentical hormone replacement therapy is working it's way into mainstream America. Due to most bioidentical hormones being unpatentable, you won't find widespread studies by pharmaceutical companies. However, the below medical research proves that BHRT has been heavily studied and researched and continues to gain use by men and women throughout the United States and other countries.

 

STUDIES - About the Science of Hormones and Hormone Replacement

 

"Testosterone pellet implants have many of the ideal features of the long-acting androgen depot (storage), including being safe, highly effective with stable clinical and biochemical effects, economical, providing flexible dosing and excellent long-acting properties due to near-zero-order dissolution. A single biodegradable implant of 600 to 1200 mg provides stable, effective, and well-tolerated placement for four to six months, and pellets can provide excellent androgen replacement in most physiologic settings."

 

- David J. Handelsman,

Pharmacology, Biology, and Clinical Applications of Androgen, 1994.

 

Low Testosterone and Type 2 Diabetes

 

"Testosterone helps men reduce body fat and improves the way their bodies handle insulin, so low testosterone levels may have serious consequences for men with diabetes, suggests Sandeep Dhindsa, M.D., of State University of New York at Buffalo. We are describing a new complication of type 2 diabetes. We are saying that the largest group of people who have low testosterone are diabetics, Dhindsa tells WebMD. It means your pituitary gland, which controls all the other hormones in your body, is not working very well. We are talking about one-third of men with diabetes being at risk of high fat mass, low muscle mass, low bone density, depression, and erectile dysfunction."

 

- Daniel DeNoon,

WebMD Medical News

 

Source: Dhindsa, S., The Journal of Clinical Endocrinology & Metabolism, November 2004; Vol. 89, pp. 5462-5468.

 

Estrogen/Androgen Parenteral Administration in Surgical Menopause More Effective than Estrogen Alone

 

"Premenopausal women who received androgen alone or a combine estrogen/androgen drug following total abdominal hysterectomy and bilateral salpingo-oophorectomy reported fewer somatic and psychological symptoms than those who received estrogen alone or placebo. Furthermore, the androgen-containing preparations induced levels of functioning that were similar to those of younger women with intact ovaries. Bearing in mind that neither androgen alone nor placebo alleviated hot flashes, the necessity for administering estrogen as well seems clear. This data suggests strong support for the conclusion that a combine estrogen/androgen regimen may serve to enhance the quality of life for women who have experienced a surgical menopause."

 

- Barbara B. Sherwin, Ph.D. and Morrie M. Gelfand, M.D.,

AM J Obstet Gynecol 1985; 151, 153-60

 

Androgens and Female Sexuality

 

"An accumulating body of data indicates that many women experience a cluster of symptoms that are responsive to testosterone treatment and may be due to androgen deficiency. Characteristically, affected women complain of low libido, persistent fatigue, and diminished wellbeing, and are found to have low circulating bio-available testosterone."

 

-Susan R. Davis, MBBS, FRACP, Ph.D.,

The Journal of Gender-Specific Medicine, 2000; 3 (1) 36-40

 

"Sustained improvements in the intensity of sexual drive, arousal, frequency of sexual fantasies, satisfaction, pleasure, and relevancy to daily life were observed in a cohort of postmenopausal women."

 

- Davis, S.R., McCloud PL Strauss, BJG, Burger H.G.,

Testosterone Enhances Estradiol’s Effects on Postmenopausal Bone Density in Sexuality, Maturitas 1995; 21, 227-236

 

Postmenopausal Estrogen and Androgen Replacement and Lipoprotein Lipid Concentrations

 

"It has been firmly established that the administration of exogenous estrogens in postmenopausal women increases HDL and decreases LDL."

 

"Possible explanation of findings is based on the suggestion that the root of administration may modulate responses to hormone therapy. Percutaneous and vaginal administration of estradiol do not cause the increases in triglycerides in the very low-density lipoprotein observed during oral therapy."

 

"Furthermore, it has been shown that subcutaneous implantation of pellets containing 40 mg of estradiol and 100 mg of testosterone did not cause any changes in cholesterol, triglycerides, or HDL from pretreatment levels. Farish, et al, likewise found that subcutaneous pellets of 50 mg of estradiol and 100 mg of testosterone had no effects on HDL fractions, but testosterone appeared to slightly enhance the LDL cholesterol, lowering effect of estradiol as it seemed to do in the present study."

 

"In summary, this study found that the addition of testosterone to a parenteral estrogen replacement regimen did not adversely influence the lipid profile of postmenopausal women thus treated for two years."

 

- Sherwin, D. B., Gelfand, M. M., Schucher, Gabor J.,

Postmenopausal Estrogen and Androgen Replacement and Lipoprotein Lipid Concentrations, A.M. J. Obstet Gynecol 1987; 156 (2) 414-419.

 

Hormonal Implants

 

"Seventeen patients whose symptoms had persisted despite treatment with oral conjugated equine estrogens 1.25 mg/day received a subcutaneously implanted pellet containing 40 mg of estradiol plus 100 mg of testosterone. Hot flash frequency did not improve with the combined implant therapy over and above the decreases reported with estrogen alone. However, these patients consistently reported a significant reduction in feelings of tiredness by one month after implantation compared to previous levels."

 

- Darwood B. Sherwin, Ph.D.,

The Role of Androgens in Menopausal Women, Proceedings from a Symposium in Atlanta, Georgia, March 26, 1988.

 

"In 1985, Sherwin and coworkers found that surgically menopausal women who received both estrogen and androgen replacement therapy had higher levels of sexual desire, sexual arousal, and fantasy than did groups of women who received estrogen alone or placebo."

 

"The enhancement of sexual functioning in women treated with both sex hormones administered intramuscularly had been confirmed by implant studies. Brincar, et al, found that the symptom loss of libido improved significantly two months after implantation of an estrogen and testosterone pellet, and the symptom reverted to pretreatment intensity four months later. Postmenopausal women who complained of absent or reduced libido that had persisted with prior estrogen therapy also reported a significant improvement in libido, enjoyment of sex, and initiation of sex by the third month following implantation of the two sex hormones. Finally, a third recent study had shown that loss libido originally reported by eighty percent of a sample of postmenopausal women was completely alleviated following an estradiol and testosterone implant."

 

- Sherwin, B., Symposium Proceedings,

Androgens and Menopausal, March 1988, Atlanta, Georgia.

 

Implant Study

 

"In 1984, Burger and colleagues measured the response of plasma lipids to subcutaneous implantation of pellets containing estradiol and testosterone. Serum cholesterol, triglycerides, and HDL levels were assayed as baseline, and again at one, three and five months after implantation. As in the studies cited above, none of the lipid parameters changed significantly throughout the course of the investigation."

 

"The addition of androgen to a postmenopausal estrogen replacement regimen consistently induces a greater sense of wellbeing and higher energy level and alleviates feelings of tiredness and lethargy often experienced by postmenopausal women. With respect to psychological functioning, the estrogen and androgen replacement regimen may also be clinically superior to estrogen alone. At least two studies have found lower psychological symptom scores and higher levels of positive mood indicators. One area of functioning where exogenous testosterone has been shown to have an undisputed beneficial effect is sexuality. Without exception, in every desire, interest, enjoyment of sex, and in some cases increase coital and orgasmic frequencies were reported. Since decreased libido was a frequent complaint in postmenopausal women, the results of these studies are of considerable clinical importance. Finally, the enhancement in physical and psychological functioning in postmenopausal women who are treated with an estrogen and androgen combination clearly does not occur at the expense of the lipid profile, at least when parenteral preparations are administered. Neither study that investigated plasma lipids in women receiving combined parenteral therapy reported changes in lipid parameters compared to pretreatment levels."

 

- Sherwin, B., The Role of Androgens in Menopausal Women, Symposium Proceedings, Androgens in the in the Menopause, March 1988, Atlanta, Georgia.

 

Exogenous Testosterone Has Been Shown to Have an Undisputed Beneficial Effect in Sexuality

 

"Without exception, in every study in which testosterone was added to an estrogen replacement regimen, increases in sexual desire, interest, enjoyment of sex, and in some cases, increased coital and orgasmic frequencies were reported."

 

- Barbara B. Sherman, Ph.D., The Role of Androgen in Menopausal Women, Proceedings from a Symposium, Atlanta, GA, March 1988.

 

Patients Who Had Been Receiving Combined Estrogen and Androgen Preparations Felt More Composed and Energetic Than Those Given Estrogen Alone

 

"Seventeen patients whose symptoms had persisted despite treatment with oral conjugated equine estrogens at 1.25 mg per day received subcutaneously implanted pellets containing 40 mg of estradiol plus 100 mg of testosterone. Hot flash frequency did not improve with the combined implant therapy over and above the decreases reported with estrogen alone. However, these patients consistently reported significant reductions in feelings of tiredness by one month after implantation compared to previous levels. On the other hand, Cardozo and coworkers did find a significant reduction in the frequency of hot flashes in women implanted with the 50 mg of estradiol and 100 mg of testosterone compared to frequencies of this symptom in subjects who had previously been treated with oral estrogens. A substantial number of these patients also reported relief from feelings of lethargy. Similarly, Brincat and colleagues also found a decrease in both hot flash frequency and lethargy when they compared the response to implants containing 50 mg of estradiol plus 100 mg of testosterone to the response to placebo."

 

- Barbara B. Sherman, Ph.D.,

The Role of Androgen in Menopausal Women, Proceedings from a Symposium, Atlanta, GA, March 1988.

 

"Suggested evidence that testosterone given in combination with estrogen may enhance mood in women from two investigations. In one study, mood changes were measured in 10 women who had been receiving a combined estrogen and androgen regimen intramuscularly for at least two years. Plasma hormone levels, sex hormone binding globulin, concentrations in mood were concurrently determined eight times during the one month study. In general, mood was positively correlated with plasma levels of estradiol and testosterone over time."

 

- Barbara B. Sherman, Ph.D.,

The Role of Androgen in Menopausal Women, Proceedings from a Symposium, Atlanta, GA, March 1988.

 

© Hormone Wizard